Cold Genesys Gets $13.57M For Bladder Cancer Treatment

Newport Beach-based Cold Genesys, a biopharmaceuticals company which is developing treatment for bladder cancer, said this week that it has raised $13.57M in a Series A funding. The funding came from Ally Bridge Group. According to the company, it is developing oncolytic immunotherapies for cancer, and is in the midst of Phase II/III trials for treating high-risk carcinoma in situ non-muscle invasive bladder cancer (NMIBC). David Nokodem, Ph.D. of Ally Bridge joins the company's board; Arthur Kuan, a founding member of Ally Bridge, becomes VP of Research and Clinical Project Management at Cold Genesys. More information »